论文部分内容阅读
目的 :比较进口与国产培高利特治疗帕金森病的疗效。方法 :在并用 (进口组有 6例不并用 )左旋多巴 苄丝肼下 ,进口组帕金森病 68例 ,男性 35例 ,女性 33例 ,年龄 64a±s 12a ,给进口培高利特从 0 .0 2 5mg·d- 1开始 ;国产组 70例 ,男性 37例 ,女性 33例 ,年龄 64a± 9a ,给国产培高利特从 0 .0 5mg·d- 1开始 ,均逐渐增至 0 .5～ 0 .75mg·d- 1,于 3mo后评定疗效。结果 :进口组总有效率 91% ,运动波动总有效率 94 % ,平均每例左旋多巴 苄丝肼剂量减少 2 8% ,国产组分别为 4 6% ,35% ,8%。差异有非常显著意义 (P <0 .0 1)。进口组副作用略多于国产组。结论 :进口培高利特治疗帕金森病效果优于国产品 ,副作用较国产培高利特略明显。
Objective: To compare the efficacy of imported and domestic pergolide in the treatment of Parkinson’s disease. METHODS: Sixty-six patients with Parkinson’s disease were enrolled in this study, including 35 males and 33 females with a mean age of 64a ± s12a (p <0.05), with imported pergolide from 0 .0 2 5mg · d-1 start; 70 cases of domestic group, 37 cases of males and 33 females, aged 64a ± 9a, to domestic pergolide starting from 0. 05mg · d-1, were gradually increased to 0. 5 ~ 0. 75mg · d-1, after 3mo assessment of efficacy. Results: The total effective rate of import group was 91%, and the total effective rate of exercise fluctuation was 94%. On average, the dosage of benserazide decreased by 28% in each group and 46%, 35% and 8% in domestic group respectively. The difference was significant (P <0.01). Import side effects slightly more than the domestic group. Conclusion: The effect of peglitant on Parkinson’s disease is better than that of domestic products, and the side effect is slightly more obvious than domestic peglitant.